Eugene Sefanov

  I recently read an article from McKinsey & Company about the digital revolution that needs to occur in order for the life sciences industry to be successful in today’s age. This is the same digital revolution that helped transform other industries, such as financial and retail. Like I mentioned in one of my previous blog […]

  In 2009, the cost for a consumer to sequence his or her genome was $49,000. It’s all the way down to $1,000 today. As the price continues to become more affordable, the frequency of the average Joe sequencing his genome will likely increase. However, many individuals are wary of the idea of knowing more […]

  Now that October is here, I thought it would be neat to look back at what our readers found most interesting last month. Below are the top five blog posts Perficient’s life sciences practice wrote in September – they’re ranked in order of popularity, with number one being the most viewed piece. 

  Check this out. Roche just developed a mobile app, which is currently being evaluated in a Phase I trial, that can help assess the severity of one’s Parkinson’s disease (PD). Here’s how it works: Patients are provided with pre-configured smartphones and, over time, are guided through a series of tests to collect data points. […]

Since the infamous Kim Kardashian Instagram post went up and the FDA issued a Warning Letter to Duchesnay, the company she was representing, a couple of things have happened. For one, Kim has issued a corrective post (i.e., ad), which outlined the safety information for Diclegis, the medication for morning sickness she is promoting. And, […]

  If you visit the Gloucester Police Department’s Facebook page, you’ll notice their posts from September 16th and 18th received thousands of likes, shares, and comments. That’s for good reason. On September 16th, the department called out five pharma CEOs with the highest salaries and urged readers to contact them and ask what they’re doing […]

  Turing Pharmaceuticals, the maker of Daraprim, a drug that treats toxoplasmosis (a parasitic disease), increased the cost of each tablet from $13.50 to $750. That’s right – more than a 5,000% increase. 

  Digital transformation (DT), the concept of leveraging digital technologies to engage with constituents (e.g., customers, patients, employees, or partners) is vital in today’s world. The audience you’re targeting expects communication to be easy and information to be readily available at any time. If they can’t get what they want from you, they’ll go somewhere […]

  These days, it appears as if most of the big contract research organizations (CROs) are using Siebel CTMS, Oracle’s clinical trial management system. In June of this year, I wrote about Quintiles’ use of Oracle Health Sciences applications, including Siebel CTMS. Now we’re talking about PPD, another top-5 CRO. 

  According to the September/October edition of the Impact Report released by the Tufts Center for the Study of Drug Development (CSDD), the reporting of adverse events (AEs) by healthcare professionals is inadequate. In particular, regulatory submissions are an issue due to the lack of critical information provided on submission forms, which can inadvertently alter […]

  We often hear the term “rare disease,” yet many of us still wonder exactly how “rare” is defined. In a recent blog post, Dr. Jonathan Goldsmith, the FDA’s Associate Director for Rare Diseases, shared some staggering statistics, as well as insights into how the FDA is making it easier to develop drugs for unusual […]

  Life sciences organizations are in the business of developing drugs and medical devices. Hitting key milestones and moving trials to the next phase has always been a priority. Throughout this entire process, the collection and analysis of clinical and safety data is essential in taking products to subsequent stages, and ultimately getting them approved […]